Search details
1.
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
Oncologist
; 28(5): 433-439, 2023 05 08.
Article
in English
| MEDLINE | ID: mdl-36640141
2.
Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.
World J Urol
; 41(4): 1069-1075, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36929410
3.
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Oncologist
; 27(12): 1041-1047, 2022 12 09.
Article
in English
| MEDLINE | ID: mdl-35979929
4.
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1103-1115, 2019 03 21.
Article
in English
| MEDLINE | ID: mdl-30779531
5.
Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression.
Mol Cancer
; 20(1): 136, 2021 10 20.
Article
in English
| MEDLINE | ID: mdl-34670568
6.
Synchronous brain metastases as a poor prognosis factor in clear cell renal carcinoma: a strong argument for systematic brain screening.
J Neurooncol
; 153(1): 133-141, 2021 May.
Article
in English
| MEDLINE | ID: mdl-33837880
7.
The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
Br J Cancer
; 118(9): 1179-1188, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29563634
8.
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
BMC Cancer
; 18(1): 1271, 2018 Dec 19.
Article
in English
| MEDLINE | ID: mdl-30567533
9.
Individualized dosing with axitinib: rationale and practical guidance.
Future Oncol
; 14(9): 861-875, 2018 Apr.
Article
in English
| MEDLINE | ID: mdl-29264944
10.
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Br J Cancer
; 117(7): 947-953, 2017 Sep 26.
Article
in English
| MEDLINE | ID: mdl-28850564
11.
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
BMC Cancer
; 17(1): 547, 2017 Aug 15.
Article
in English
| MEDLINE | ID: mdl-28810837
12.
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.
Invest New Drugs
; 34(1): 41-8, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26572909
13.
Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report.
Anticancer Drugs
; 27(5): 427-32, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-27045782
14.
A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.
Br J Cancer
; 113(8): 1148-57, 2015 Oct 20.
Article
in English
| MEDLINE | ID: mdl-26372698
15.
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Cancer
; 120(12): 1871-80, 2014 Jun 15.
Article
in English
| MEDLINE | ID: mdl-24634003
16.
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Lancet Oncol
; 14(6): 552-62, 2013 May.
Article
in English
| MEDLINE | ID: mdl-23598172
17.
Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study.
Clin Genitourin Cancer
; 22(2): 295-304.e6, 2024 04.
Article
in English
| MEDLINE | ID: mdl-38105152
18.
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Eur J Cancer
; 201: 113589, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38382153
19.
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Eur J Cancer
; 204: 114048, 2024 Apr 08.
Article
in English
| MEDLINE | ID: mdl-38653033
20.
Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma.
Clin Genitourin Cancer
; 21(2): e35-e43, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36272959